0001493152-26-022791
SEC filingQ1 2026 delivered sharply lower revenue from reduced AI Nose sales volume in healthcare-adjacent applications, driving gross losses, though operating and net losses narrowed versus prior year due to disciplined expense management amid strategic product investments.
Ainos, Inc. (AIMD) reported Q1 2026 results reflecting a strategic pivot in its AI Nose technology deployment, with revenue falling 99.8% to $161 from $106K in the prior-year quarter. Management attributes this primarily to lower sales volume in healthcare-adjacent applications, signaling a shift toward industrial opportunities while maintaining development momentum.
Gross profit inverted to a $602 loss from an $88K profit, with gross margin at -373.9%. The swing stems directly from the reduced sales volume, as lower revenue failed to cover costs that declined proportionally but not sufficiently to preserve profitability. Management's discussion confirms the decrease in gross profit ties to this volume drought in AI Nose programs.
Looking forward, management expects continued development spending over the next twelve months to advance product plans, though going concern realization depends on securing uncertain future funding. This quarter's narrower losses amid revenue challenges demonstrate operational resilience, setting the stage for potential industrial AI Nose catalysts to drive volume recovery and margin expansion.